InvestorsHub Logo
Followers 32
Posts 656
Boards Moderated 0
Alias Born 06/14/2012

Re: hyperopia post# 670701

Wednesday, 02/07/2024 2:18:33 PM

Wednesday, February 07, 2024 2:18:33 PM

Post# of 717472

Northwest Bio (Flaskworks and Advent) have actually further developed that commercial system, which was capable of producing one patient’s treatment (10-12 doses) at a time, into an industrial commercial system that is capable of producing 10-12 patient’s treatments (100-120 doses) at a time]



I don't think the Flaskworks device has changed from creating a batch of doses for one patient to a dozen or so.

From the PR, https://www.prnewswire.com/news-releases/northwest-biotherapeutics-moves-from-optimization-of-flaskworks-prototype-to-fabrication-of-gmp-compliant-units-for-installation-validation-and-final-testing-prior-to-regulatory-certification-302054769.html:

Manufacturing using the "closed" Flaskworks system will also enable products for multiple patients (potentially up to a dozen or so) to be produced in a single (larger) manufacturing lab at the same time. Under the present "open" process (as with most cell therapy production processes to date), only 1 patient's product can be made at a time in each manufacturing lab, and the lab must go through special cleaning in between each product.


I believe the PR is saying you can have multiple devices, "a dozen or so", in the same space (or the same number of personnel?) as the manual process would take up, also in a less stringent clean room. I would imagine much more than 12 devices can be set up in the space of those clean rooms. Still, great confirmation of these fully closed and automated devices the size of an Epson ink jet printer. AND STILL A VERY BIG DEAL!
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News